Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients
This study is a cross sectional observational study to evaluate the prevalence of HLA-B*5701 in the major French ethnotypes.
Any HIV-1 infected subject will be eligible for this study including antiretroviral therapy (ART) naÃ-ve and experienced subjects irrespective of abacavir use, as well as subjects previously tested for HLA-B*5701. Subjects will be approached during a standard clinic visit, and all subjects will be consented prior to any study specific procedure. Subjects will be asked to provide a tissue sample (cheek cells and blood sample) which will be used to assess HLA-B*5701 status by central and local methodologies.
|Study Design:||Time Perspective: Prospective|
|Official Title:||Prospective Epidemiological Study of the Prevalence of HLAB*5701 in HIV-1 Infected Patients|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00441688
|Study Director:||GSK Clinical Trials, MD PhD||GlaxoSmithKline|